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High-mobility group box 1 protein (HMGB1) is a
nuclear component, but extracellularly it serves
as a signaling molecule involved in acute and
chronic inflammation, for example in sepsis
and arthritis. The identification of HMGB1 inhib-
itors is therefore of significant experimental and
clinical interest. We show that glycyrrhizin, a
natural anti-inflammatory and antiviral triter-
pene in clinical use, inhibits HMGB1 chemo-
attractant and mitogenic activities, and has a
weak inhibitory effect on its intranuclear DNA-
binding function. NMR and fluorescence stud-
ies indicate that glycyrrhizin binds directly to
HMGB1 (Kd 150 mM), interacting with two
shallow concave surfaces formed by the two
arms of both HMG boxes. Our results explain
in part the anti-inflammatory properties of gly-
cyrrhizin, and might direct the design of new
derivatives with improved HMGB1-binding
properties.
INTRODUCTION
Inflammation, in the broadest sense, is a physiological,
protective response to injury and infection. A complex net-
work of cellular responses leads to the resolution of infec-
tion and/or the repair of the damaged tissue. Alterations of
this process, however, are at the basis of many acute and
degenerative diseases, including, among others, sepsis,
atherosclerosis, and arthritis.
High-mobility group box 1 (HMGB1) protein is a nuclear
protein that acts as an architectural chromatin-binding
factor [1, 2]. HMGB1 was identified in 1999 as an impor-
tant extracellular mediator of inflammation [3]. When cells
die in a nonprogrammed way (necrosis), they release
HMGB1 by simple diffusion; in contrast, cells that die in
a programmed way (apoptosis) avidly retain HMGB1
bound to chromatin remnants even after eventual cell lysisChemistry & Biology 14,[4]. This differential behavior between necrotic and apo-
ptotic cells makes HMGB1 the primary signal of tissue
damage; extracellular HMGB1 promotes local and sys-
temic responses in the organism, including inflammation
and the activation of innate and adaptive immunity [5–7].
Activatedmonocytes, macrophages, neutrophils, plate-
lets, and dendritic and NK cells can also release HMGB1
in the extracellular space [3, 8–10]. These cells do not
die, but actively secrete HMGB1 in a process that is inde-
pendent of the endoplasmic reticulum and the Golgi
apparatus and depends on HMGB1 relocalization from
the nucleus to special organelles, the secretory lysosomes
[11–13].
Extracellular HMGB1 activates a large number of differ-
ent physiological responses in different cell types, and can
be considered a cytokine [14]. Its beneficial roles include
the promotion of tissue regeneration, by attracting stem
cells and inducing them to proliferate [15, 16]. However,
HMGB1 plays a pathogenetic role in severe sepsis and
arthritis [17, 18], and may play a role in atherosclerosis
and cancer [19, 20]. Antibodies against HMGB1 can re-
verse sepsis caused by peritonitis in mice [21]; therefore,
the identification of small-molecule inhibitors of HMGB1
might have significant therapeutic importance.
A large number of anti-inflammatory drugs exist, and
the mode of action of several of these is unknown. As
HMGB1 was recognized as an important proinflammatory
molecule only fairly recently, it looked likely that one or
more of the clinically effective anti-inflammatory drugs
could exert their action by interfering with this relatively
unexplored inflammatory axis. Our attention focused
on glycyrrhizin, a glycoconjugated triterpene (Figure 1A)
produced by the licorice plant, Glycyrrhiza glabra. In
Japan, glycyrrhizin is administered at high doses (up to
140 mg/day) to patients with hepatitis B and C [22].
Remarkably, our own work has highlighted a possible
role of HMGB1 in the pathogenesis of hepatitis [23]. The
convergence of these pieces of information identified
glycyrrhizin as a candidate inhibitor of the HMGB1-depen-
dent inflammatory axis.
We show here that indeed glycyrrhizin inhibits the
chemoattractant and mitogenic activities of HMGB1.431–441, April 2007 ª2007 Elsevier Ltd All rights reserved 431
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Glycyrrhizin Inhibits HMGB1 ActivitiesFigure 1. Glycyrrhizin Inhibits the Chemotactic Activity of HMGB1
(A) The chemical structure of glycyrrhizin. Carbenoxolone is a derivative where the two glucuronic acid residues are substituted by a succinyl residue.
(B) 3T3 fibroblasts were subjected to chemotaxis assays in Boyden chambers where 0.1 nM fMLP, 1 nM HMGB1, or no chemoattractant was added
in the lower chamber, together with the indicated concentrations of glycyrrhizin. The data represent the average ± SD of three replicates; the
experiments were replicated at least three times. The inhibitory effects of glycyrrhizin on HMGB1-induced cell migration were highly significant
(p < 0.001 in ANOVA analysis), whereas they were not statistically significant on fMLP-induced cell migration.Glycyrrhizin binds directly to each of the two HMG boxes
of HMGB1, as shown by NMR and fluorescence studies.
RESULTS
Glycyrrhizin Inhibits the Chemoattractant Activity
of HMGB1
HMGB1 has chemoattractant activity on endothelial,
smooth muscle, and vessel-associated stem cells [15,
24]. In addition, we found that it is also a powerful chemo-
attractant for the widely available mouse 3T3 fibroblasts
(Figure 1B). Glycyrrhizin interfered with HMGB1-elicited
cell migration of 3T3 fibroblasts in a dose-dependent
manner (Figure 1B; p < 0.001 in ANOVA two-way test).
The number of 3T3 cells migrating in response to 1 nM
HMGB1 was reduced by about half at a concentration of432 Chemistry & Biology 14, 431–441, April 2007 ª2007 Elsevi50 mM glycyrrhizin (IC50 = 49 ± 1 mM in a sigmoidal log
dose response curve, r2 = 0.93). Glycyrrhizin did not affect
cell migration elicited by fMLP, a well-known chemo-
attractant, even at a concentration of 200 mM. This shows
that glycyrrhizin does not affect the general mobility of
fibroblasts, and suggests that its effect is specific on
HMGB1-elicited chemotaxis. Moreover, glycyrrhizin had
no statistically significant effect on the mobility of fibro-
blasts in the absence of chemoattractant (Figure 1B).
Glycyrrhizin Inhibits theMitogenic Activity of HMGB1
on Vessel-Associated Stem Cells
HMGB1 promotes the in vitro proliferation of vessel-
associated stem cells (mesoangioblasts) in the absence
of fetal calf serum [15]. When added to mesoangioblasts
in culture, increasing concentrations of glycyrrhiziner Ltd All rights reserved
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Glycyrrhizin Inhibits HMGB1 ActivitiesFigure 2. Glycyrrhizin Inhibits the Mito-
genic Activity of HMGB1 on Vessel-
Associated Stem Cells (Mesoangio-
blasts)
D16mesoangioblasts were grown in RPMIme-
dium containing no additions, 1 nM HMGB1
with the indicated concentration of glycyrrhi-
zin, or 20% fetal calf serum (FCS). Each point
represents the mean of three replicates. Error
bars are omitted to avoid clutter; the standard
deviation was between 2% and 15% of the
average. The experiment was repeated three
times. The inhibitory activity of glycyrrhizin
on HMGB1-induced stem-cell proliferation
is highly significant (p < 0.001 in ANOVA
analysis).inhibited the mitogenic activity of HMGB1 in a dose-
response manner; in the presence of 200 mM glycyrrhizin
no mitogenic activity of HMGB1 was noted, and the cell
counts were indistinguishable from those of cultures
where no serum and no HMGB1 were present (Figure 2).
Conversely, glycyrrhizin showed no effect on growth of
mesoangioblasts in the presence of 20% fetal calf serum
(data not shown).
Glycyrrhizin Binds Directly to HMGB1: Identification
of the Binding Surface by NMR
Binding of glycyrrhizin to HMGB1 was probed using NMR
chemical-shift differences (CSD), a highly sensitive tool for
proving interactions and formapping binding sites and de-
tecting residues which directly interact with the ligand or
that are indirectly affected by the association. Two-dimen-
sional 1H-15N HSQC spectra of full-length 15N-labeled
HMGB1 were recorded to monitor the changes in the
1H-15N chemical shifts of the backbone amide groups in-
duced by successive additions of glycyrrhizin. A compar-
ison of the spectra in the absence and presence of a 4-fold
excess of glycyrrhizin is shown in Figure 3A. The complex
is in fast exchange on the chemical-shift timescale
(Figure 3B); this facilitated the assignments of the reso-
nances in the complex, which were obtained following
the crosspeaks of HMGB1 upon addition of increasing
amounts of glycyrrhizin.
To identify the interaction surface, the average chemi-
cal-shift changes between the free and the bound state
were plotted versus the HMGB1 residue numbers (Fig-
ure 3C). Most of the protein residues do not experience
relevant chemical-shift perturbation, indicating that gly-
cyrrhizin does not alter the overall protein structure. The
global preservation of the secondary structure was further
confirmed by circular dichroism (CD) spectroscopy
(Figure 3F).
Resonances with significant CSD (deviating more than
one standard deviation from the mean CSD) included res-
idues F17, Q20 (side-chain protons), R23, E25, K43, andChemistry & Biology 14, 4C44 for box A (Figures 3C, 4A, and 4B) and R109, I112,
D123, and A125 for box B (Figures 3C, 4C, and 4D). No in-
teractions were observed with the linker region between
the two boxes and the C terminus. The individual peaks
corresponding to the acidic tail residues could not be as-
signed because of high spectral overlap and exchange
with the solvent [25]; however, these peaks did not shift
upon addition of glycyrrhizin, excluding their involvement
in the binding.
Previous structural studies have clearly demonstrated
that the two HMG boxes behave as rigid independent do-
mains that do not interact with each other in the context of
the full-length protein [25]; we therefore verified whether
glycyrrhizin binds similarly to the two individual HMG
boxes (15N-labeled box A and box B) (Figures 3D and
3E). Indeed, residues mostly affected by the presence of
the ligand all clustered on the first two helices of both
HMG boxes, and coincided with the residues showing
high CSD in the full-length protein. Additional residues lo-
cated on helices 1 and 2 (H26, K42, E107, K113, G122,
G129, M133) were more affected in the isolated domains
than within the entire protein. This effect might be due to
a slightly different orientation of the ligand, or to small
structural differences of the entire protein when compared
to the isolated domains.
On both HMG boxes (whether in HMGB1 or in isolation),
the binding site is located at the crux of the typical L-shape
fold, which has a small solvent-exposed hydrophobic sur-
face suitable for favorable van der Waals interactions with
the triterpene scaffold of glycyrrhizin (Figure 4). Interest-
ingly, in the upfield region of the monodimensional proton
spectrum of both HMGB1 and box A, variations in chem-
ical shifts are also observed for the well-resolved 1H
methyl resonances of V19 and V35, located on helices 1
and 2 of box A, further suggesting an involvement of this
region in the binding (see Figure S1 in the Supplemental
Data available with this article online). The titration exper-
iments also indicate that helix 3 is not involved in the bind-
ing (Figures 3C–3E and 4).31–441, April 2007 ª2007 Elsevier Ltd All rights reserved 433
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Glycyrrhizin Inhibits HMGB1 ActivitiesFigure 3. NMR Titration of HMGB1, Box A, and Box B with Glycyrrhizin
(A) Superposition of the HSQC spectra of HMGB1without (black) andwith (red) a 4-fold excess of glycyrrhizin. The spectra were acquired at 600MHz,
T = 298K. Protein concentration was 0.25 mM, in 20 mM phosphate buffer (pH 7.3), 150 mM NaCl, 5 mM DTT.
(B) A selected region of HMGB1 spectra during the titration with glycyrrhizin (0.5, 1, 1.5, 2, 3, 4 equivalents of ligand). The starting and end points of the
titration are represented in black and red, respectively. The largest shifts were observed for the amino group of Q20. The observed chemical-shift
changes are a continuous and monotonic function of the amount of added peptide, indicating that the binding is in the fast exchange limit on the
NMR timescale.
(C–E) Histograms showing the value of the CSD in HMGB1 (C), box A (D), and box B (E) induced upon bindingwith glycyrrhizin (4-fold excess). Residue
numbers are indicated on the x axis (residues for which CSD is missing are either prolines or could not be detected because of exchange with the
solvent at pH 7.3); the asterisks indicate the CSD of the amino group of Q20. The continuous line represents the average chemical-shift difference;
the dotted line represents the average chemical-shift difference plus one standard deviation. The amino acids mostly affected by the addition of gly-
cyrrhizin are located on the first two helices of box A and box B (helices are schematically represented at the top of the histograms).
(F) CD spectra of HMGB1 (3 mM)without (continuous line) and with (dotted line) 200 mMglycyrrhizin. The spectra show that upon addition of an excess
of ligand, the secondary structure of the protein does not change. Spectra were acquired at 20C in 10 mM phosphate buffer (pH 7.3), 10 mM NaCl.434 Chemistry & Biology 14, 431–441, April 2007 ª2007 Elsevier Ltd All rights reserved
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Glycyrrhizin Inhibits HMGB1 ActivitiesFigure 4. Mapping of the Glycyrrhizin Binding Sites and Model of Interaction
(A) Ribbon and (B) surface representation of box A (PDB code: 1aab); the side chains of residues in the full-length protein showing CSD larger than
the mean value plus one standard deviation (F17, Q20, R23, E25, K43, C44) are shown in red.
(C) Ribbon and (D) surface representation of box B (PDB code: 1hmf); the side chains of residues in the full-length protein showing CSD larger than
the mean value plus one standard deviation (R109, I112, D123, A125) are shown in red.
(E) Model of interaction of glycyrrhizin with box A; HADDOCK restraints and hydrophobic residues are shown in red and magenta, respectively.
Glycyrrhizin (cyan) accommodates at the junction of the two arms of the L-shape fold.
(F) Zoom of the binding site: glycyrrhizin establishes favorable van der Waals interactions with the hydrophobic side chains of Y15, F37, A16, and V19
(magenta). The complex is further stabilized by a bifurcated electrostatic interaction between the carboxylate of glycyrrhizin and the amine of K42 and
the hydroxyl group of Y15 (yellow dashed lines). The carbonyl group of glycyrrhizin forms a stable hydrogen bond with the guanidinium group of R23
(red dashed line).We repeated the titrationswith carbenoxolone, a deriva-
tive of glycyrrhizin where the dimer of glucuronic acid is
substituted by a succinyl moiety (Figure 1A). In the case
of box A, we found that the highest chemical-shift pertur-
bations of the backbone 1H and 15Nwere again located on
the first two helices, as observed for glycyrrhizin (data not
shown). However, the spectra for box B and the full-length
protein at higher carbenoxolone concentrations were of
low quality, and showed evidence of aggregation.Chemistry & Biology 14,Modeling of Glycyrrhizin Interaction with Box A
To further characterize the interaction between glycyrrhi-
zin and the HMG boxes, we ran classical X-filtered exper-
iments on the box A:glycyrrhizin complex. Because of the
modest affinity of glycyrrhizin (see below), we observed
very few unambiguous intermolecular interactions, which
were not sufficient to calculate a structure of the complex.
We therefore adopted the HADDOCK strategy [26], a
recent but well-established procedure which uses431–441, April 2007 ª2007 Elsevier Ltd All rights reserved 435
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ing, both of proteins and of small molecules [27]. We ob-
tained bundles of solutions with similar features (Fig-
ure S2), where triterpene accommodates at the junction
of the two arms, establishing favorable van der Waals in-
teractions with the hydrophobic side chains of A16, Y15,
V19, and F37 (Figures 4E and 4F), whereas the sugar
moieties point away from the protein. The model predicts
stabilizing interactions between the carboxylate of glycyr-
rhizin and both the side chain of K42 and the hydroxyl
group of Y15. The carbonyl group of glycyrrhizin is also
predicted to create a hydrogen bond with the guanidinium
group of R23 (Figure 4F).
The HADDOCK calculations suggest similar inter-
actions between box B and glycyrrhizin: the ligand ac-
commodates on the shallow concave surface formed by
the two arms of the HMG box, creating favorable hydro-
phobic interactions between its triterpene scaffold and
the side chains of F101, F102, I121, and A125. Similarly
to box A, the model predicts electrostatic interactions of
the carboxyl and carbonyl groups of the ligand with
K126 and R109, respectively (Figure S3). Unfortunately,
in the case of box B, we could not observe intermolecular
nuclear Overhauser effects (nOes) that could further sup-
port the model.
Binding Constants for the Glycyrrhizin:HMGB1
Complex
Dissociation constants were estimated by monitoring the
change of individual resonance chemical shifts of the sin-
gle boxes as a function of ligand concentration. Plots of
the chemical-shift changes of two representative residues
for box A (R23) and box B (R109) as a function of ligand
concentration are shown in Figures 5A and 5B; assuming
a simple binary interaction between single boxes and gly-
cyrrhizin, we derived Kd values of 103 ± 25 mM and 87 ±
35 mM for box A and box B, respectively. Because of the
low quality of the NMR spectra of the full-length protein
in the presence of glycyrrhizin at stoichiometric ratios
higher than 1:4 (HMGB1:glycyrrhizin), we could not follow
the NMR signals up to saturation to obtain a reliable esti-
mate of the binding constants.
We investigatedwhether intrinsic fluorescence could be
used to monitor the interaction of HMGB1 with glycyrrhi-
zin. Two conserved tryptophans (W48 and W132 in box
A and box B, respectively) are buried inside the hydropho-
bic core of the domain and do not belong to the proposed
ligand binding site; as expected, no noticeable change in
their fluorescencewas observed (data not shown). Two ty-
rosines (Y15 and Y108 in box A and box B, respectively)
are close to the residues showing chemical-shift perturba-
tions; tyrosine fluorescence decreases upon glycyrrhizin
addition (Figure 5C). Nonlinear least-squares fitting of
the data yields dissociation constants of 170 ± 3 mM for
box A and 140 ± 3 mM for box B, assuming a 1:1 stoichi-
ometry of isolated boxes and glycyrrhizin. The binding of
glycyrrhizin to both HMG boxes, together with the struc-
tural independence of the boxes inside HMGB1, strongly
suggest that the full-length protein has two independent436 Chemistry & Biology 14, 431–441, April 2007 ª2007 Elsevibinding sites for glycyrrhizin. We therefore fitted our
fluorescence data for the full-length protein assuming a
1:2 (HMGB1:glycyrrhizin) binding stoichiometry and two
independent dissociation constants, KdA and KdB, for the
binding site on box A and box B, respectively. Nonlinear
least-squares fitting of the data did not yield two
Figure 5. Glycyrrhizin Binding Isotherms to Box A, Box B, and
HMGB1
(A and B) Weighted average of the R23 (A) and R109 (B) amide 1H and
15N chemical-shift changes as a function of added glycyrrhizin. As-
suming a simple binary interaction between single boxes and glycyrrhi-
zin, nonlinear curve fitting yields values for Kds of 103 ± 25 mMand 87 ±
35 mM for box A and box B, respectively.
(C) Tyrosine fluorescence (excitation 273, emission 325 nm) was mea-
sured (in arbitrary units; a.u.) upon titration of glycyrrhizin into solutions
of box A (triangles), box B (circles), and HMGB1 (squares). Symbols
correspond to experimental data, whereas continuous curves are de-
rived according to Equations 2 and 3 described in Experimental Proce-
dures. Calculated dissociation constants are 170 ± 3 mM for box A and
140 ± 3 mM for box B, assuming a 1:1 association of isolated boxes and
glycyrrhizin, and 156 ± 3 mM for both binding sites, assuming a 1:2
association of HMGB1 and glycyrrhizin.er Ltd All rights reserved
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Glycyrrhizin Inhibits HMGB1 ActivitiesFigure 6. Glycyrrhizin Has a Limited Effect on the Intranuclear
Mobility of HMGB1
(A) FRAP analysis of HMGB1-GFP in living 3T3 fibroblasts incubated in
the presence or absence of 100 mM glycyrrhizin for 4 hr or overnight.
Compare for reference the mobility of an HMGB1 mutant unable to
bind DNA (mutHMGB1). Dots indicate mean values, and error bars in-
dicate standard error, from eight cells. Also shown is an enlargement of
the recovery kinetics in the first 2 s. The effect of glycyrrhizin is statis-
tically significant (p < 0.01 in paired two-way t test).
(B) FRAP analysis of HMGB1-GFP in 3T3 fibroblasts undergoing
apoptosis for 16 hr after addition of 2 ng/ml TNF-a and 35 mM cyclo-
heximide in the presence or absence of 100 mM glycyrrhizin. Only
two cells per class are shown out of seven analyzed, to avoid clutter.
The difference between treated and untreated apoptotic cells is not
statistically significant (Mann-Whitney test). For reference, the recov-
ery kinetics of HMGB1 in living cells is indicated.Chemistry & Biology 14,statistically different values for KdA and KdB but rather re-
sulted in a common value of 156 ± 3 mM (Figure 5C). This
value is similar to the value obtained for the single boxes,
further suggesting that the binding of glycyrrhizin to the
full-length protein is noncooperative and does not result
in an improved binding affinity relative to single boxes.
These results suggest also that the acidic tail does not
interfere in the binding of glycyrrhizin to HMGB1.
Glycyrrhizin Interferes Only Mildly with the
Intranuclear Association of HMGB1 with DNA
Interestingly, our proposed glycyrrhizin binding site on
box A partially overlaps with the DNA binding site, as de-
duced from the crystal structure of box A complexed to
cisplatin-modified DNA [28], and from other HMG box-
DNA structures [29]. This raised the possibility that glycyr-
rhizin might interfere with the DNA-binding function of
HMGB1. We then tested by fluorescence recovery after
photobleaching (FRAP) whether glycyrrhizin would in-
crease the mobility of intranuclear HMGB1, and reduce
its residence time on chromatin (Figure 6A). In the pres-
ence of 100 mMglycyrrhizin, the mobility of HMGB1-green
fluorescent protein (GFP) increased a little after 4 hr (p <
0.01, ANOVA), and slightly more after overnight incuba-
tion, indicating that glycyrrhizin can indeed interfere with
the binding of HMGB1 to DNA in living cells. However,
the glycyrrhizin-induced increase in the mobility of intra-
nuclear HMGB1-GFP was quantitatively modest, and far
from the mobility of an HMGB1-GFP mutant that does
not bind DNA [30]. This suggests that the effect of glycyr-
rhizin on the intranuclear functions of HMGB1 is modest.
We also tested whether glycyrrhizin might interfere with
the tight binding of HMGB1 to apoptotic chromatin [4].
Fibroblasts were induced to undergo apoptosis after ex-
posure to TNF-a, in the presence or absence of 100 mM
glycyrrhizin, and the mobility of HMGB1-GFP was mea-
sured by FRAP. HMGB1-GFP was immobilized both in
cells treated and not treated with glycyrrhizin (Figure 6B).
DISCUSSION
We have shown that glycyrrhizin, a natural triterpene gly-
coconjugate derived from the root of licorice (Glycyrrhiza
glabra), inihibits the chemotactic and mitogenic functions
of HMGB1. Both NMR and fluorescence studies indicate
that glycyrrhizin binds to both HMG boxes of HMGB1,
without distorting their secondary structure in a significant
way, as indicated by the absence of changes in the CD
spectra.We also showed that themoiety of glycyrrhizin re-
sponsible for binding is its triterpene ring, because re-
placement of the glucuronic acid residues with a succinyl
residue, as present in the drug carbenoxolone, does not
interfere in the association to box A.
Chemical-shift perturbation experiments indicate that
amino acids interacting with glycyrrhizin cluster at the
junction of the two arms of the classical L-shape fold of
both HMG boxes. A data-driven docking program that
uses chemical-shift perturbation data, HADDOCK [26],
generates a model of interaction between box A and431–441, April 2007 ª2007 Elsevier Ltd All rights reserved 437
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interactions in complex stabilization, and suggests the
presence of favorable hydrophilic interactions between
the carboxylate and carbonyl groups of glycyrrhizin and
the conserved positively charged residues on both HMG
boxes (R23, K42, R109, K126). The glucuronic acids do
not appear to participate in the binding. This interaction
pattern is reminiscent of the one described for DNA poly-
merase b: in this case as well, carbenoxolone binds on the
surface of the protein, optimizing the interactions with the
hydrophobic cleft formed by two helices [31].
Notably, the binding sites for glycyrrhizin on the HMG
boxes partially overlap with the DNA binding sites, shield-
ing residues such as R23, which is well known to be crucial
for DNA binding [28]; in fact, glycyrrhizin reduces to a small
extent the binding of HMGB1 to DNA in living cells, as as-
sayed by quantitative microscopy. The modest effect of
glycyrrhizin on the intranuclear function of HMGB1 is in
agreement with the absence of cytotoxicity even at high
glycyrrhizin concentrations and with the good pharmaco-
logical tolerability of glycyrrhizin in rodents and humans
[32]. This is possibly due to the vast difference in the affin-
ity of glycyrrhizin and distorted DNA for HMGB1 (on the or-
der of 100 mM and 10 nM, respectively) [33]. Interestingly,
glycyrrhizin does not cause the release of HMGB1 from
apoptotic chromatin, implying that it will not produce par-
adoxical proinflammatory responses to apoptotic cells.
The chemotactic and mitogenic properties of HMGB1
depend on its interaction with the receptor of advanced
glycation end products (RAGE) [15]. It is interesting to
note that the RAGE binding surface on HMGB1 is repre-
sented by the stretch of basic amino acids between box
B and the acidic tail [15], and does not correspond to
the surfaces engaged by glycyrrhizin. Moreover, the IC50
for the inhibition of HMGB1-induced chemotaxis by gly-
cyrrhizin is 50 mM for fibroblasts (Figure 1) and 15 mM for
endothelial cells (F.D.M. and M.E.B., unpublished data),
whereas the dissociation constant for glycyrrhizin and
HMGB1 is about 150 mM (Figure 5). These results suggest
that another surface molecule, possibly belonging to the
integrin family as recently suggested [34], also takes part
in the binding of HMGB1 to RAGE, and favors the binding
of glycyrrhizin to HMGB1 on the cell surface.
Glycyrrhizin is known to interfere with 11b-hydroxyste-
roid dehydrogenase type 2, leading to an enhancedminer-
alcorticoid effect of cortisol [32]. However, we tested the
effect of cortisol on cell migration induced by HMGB1
and fMLP, and found none (data not shown). This sug-
gests that the effects on 11b-hydroxysteroid dehydroge-
nase type 2 and cell migration are distinct and separate.
SIGNIFICANCE
Our data identify in HMGB1 a target of glycyrrhizin,
a useful and well-tolerated drug that has been used
for decades in Japan to treat patients with hepatitis
[35–37]. In turn, this suggests that HMGB1 is involved
in the pathogenesis of hepatitis, and in fact we have
recently shown that glycyrrhizin reduces liver disease438 Chemistry & Biology 14, 431–441, April 2007 ª2007 Elsevin a mouse model of hepatitis B by interfering with
HMGB1-induced recruitment of neutrophils and other
inflammatory cells to the liver [23]. HMGB1 plays an
important and partially unexplored role in a number
of pathologies, including sepsis, rheumatoid arthritis,
and atherosclerosis; the availability of a small-mole-
cule inhibitorwill facilitate futurestudieson thebiology
ofHMGB1. Themolecularmodel of theHMGB1-glycyr-
rhizin interaction may also help in designing more po-
tent drugs with improved HMGB1-binding properties.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Proteins
Recombinant HMGB1 constructs comprising box A (residues 1–89),
box B (residues 90–175), and the full-length protein were cloned in a
modified pET-24d vector (Novagen, Madison, WI) expressing a protein
with an N-terminal 6-His tag, removable by cleavage with TEV prote-
ase. After expression and cleavage with TEV protease, the proteins
have a residual N-terminal three-residue tag (GAM). Escherichia coli
cells were grown at 37C until the optical density at 600 nm reached
0.8 absorbance units. Gene expression was induced by the addition
of isopropyl b-D-1-thiogalactopyranoside (IPTG) to a final concentra-
tion of 1 mM. After 18 hr incubation at 25C with shaking, cells were
harvested by centrifugation. The cells were resuspended in lysis buffer
(20 mM Tris-HCl [pH 8.0], 0.15 M NaCl, 10 mM imidazole, 2 mM
b-mercaptoethanol, 0.2% NP40) and lysed by sonication. Cell debris
was removed by centrifugation at 13,000 rpm for 30 min at 4C in a mi-
crocentrifuge. The soluble 6-His-tagged HMGB1 protein was purified
from the supernatant by affinity chromatography using Ni2+-NTA aga-
rose resin (Qiagen, Hilden, Germany). After several washing steps, pro-
tein was eluted in 20 mM Tris (pH 8.0), 0.15 M NaCl, 0.3 M imidazole,
2 mM b-mercaptoethanol. The 6-His tag was removed by overnight
incubation at 25C with TEV protease. During incubation, the sample
was dialyzed against 20 mM Tris (pH 8.0), 0.15 M NaCl, 2 mM b-
mercaptoethanol. The uncleaved 6-His-tagged protein and the TEV
protease were then removed by repassing the sample over Ni2+-NTA
resin. The protein sample was further purified on a HitrapQ ion-ex-
change column followed by gel filtration on a Superdex-75 column
(Amersham Biosciences, Milan, Italy) equilibrated in 40 mM Tris (pH
8.0), 0.2MNaCl, 3mMdithiothreitol (DTT). All the purifiedHMGB1poly-
peptides were exchanged into appropriate buffers for NMR (20 mM
sodium phosphate [pH 7.3], 0.15 M NaCl, 5 mM DTT, 0.02% NaN3,
5% v/v D2O). Uniformly
15N- and 15N/13C-labeled proteins were pre-
pared using M9 minimal bacterial growth media appropriately supple-
mentedwith 15N-labeled ammoniumchloride and 13C-labeled glucose.
Protein concentration was determined measuring the absorbance at
280 nm considering molar extinction coefficients of 9,186, 10,810,
and 19,666 M1 cm1 for box A, box B, and HMGB1, respectively.
Chemotaxis and Cell Proliferation Assays
Chemotaxis assays were performed as described [15], with the follow-
ing differences: mouse 3T3 fibroblasts were used, filters were coated
with a drop of 50 mg/ml fibronectin (Roche, Mannheim, Germany), and
cell migration lasted 4 hr.
Cell proliferation assays were executed as described [15].
NMR Measurements
NMR spectra were recorded at 298K on a Bruker Avance 600 MHz
spectrometer (Karlsruhe, Germany) equipped with inverse triple-reso-
nance cryoprobe and pulsed-field gradients. Spectra were processed
with NMRPipe [38] and analyzed using XEASY [39] and/or PIPP [40].
The 1H,13C,15N assignment of the backbone resonances of box A,
box B, and full-length HMGB1 were obtained as described [25] using
uniformly 15N,13C-labeled samples. NMR assignments for HMGB1
and fragments thereof have been deposited in the BMRB data bankier Ltd All rights reserved
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Glycyrrhizin Inhibits HMGB1 ActivitiesTable 1. Residues Showing Strong Chemical-Shift Difference, nOe Interactions with Glycyrrhizin, and Flexible
Residues
Domain CSD nOe Flexible Residues
Box A F17, Q20, R23, E25, H26,a K42,a K43a Y15-H28b; F37-H27b; F37-H25b M12-W48a
Box B E107,a R109, K113,a G122, D123, A125, G129, N133a n.d. P97-A137a
n.d., not determined.
a These amino acids have been used as passive restraints in the HADDOCK calculation.
b These hydrogens belong to methyl groups in glycyrrhizin (Figure 1A).(http://www.bmrb.wisc.edu) with accession numbers 15148 and
15149. Typical protein concentration for NMR titration experiments
was 0.3 mM in 20 mM phosphate buffer (pH 7.3), 150 mM NaCl, 5
mM DTT. In order to minimize dilution and NMR signal loss, titrations
were carried out by adding to the protein samples small aliquots of
a concentrated (10 mM) ligand stock solution (glycyrrhizic acid mono-
ammonium salt trihydrate, 98% purity [Acros Organics, Geels, Bel-
gium], carbenoxolone disodium salt, 98% purity [Sigma, St. Louis,
MO]) in 20 mM phosphate buffer, 150 mM NaCl, at pH 7.3. For each
titration point (typically 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4 equivalents of li-
gand), a two-dimensional water-flip-back 15N-edited HSQC spectrum
was acquired with 512 (100) complex points, 55 ms (60ms) acquisition
times, apodized by 60 shifted squared (sine) window functions, and
zero filled to 1024 (512) points for 1H (and 15N), respectively. Assign-
ment of the corresponding amide groups in the complexes was
made by following individual crosspeaks through the titration series.
For each residue, the weighted average of the 1H and 15N chemical-
shift difference was calculated as CSD= ½ðDd2HN+ Dd2N=25Þ=21=2
[41].
Binding constants of glycyrrhizin to single boxes (box A and box B)
were estimated by monitoring the variation of CSD of individual peaks
(eight peaks for each box). Assuming a simple binary reaction between
protein and ligand, dissociation constants were obtained from least-
squares fitting of CSD as a function of total ligand concentration
according to the relation (Equation 1):
di =
b
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2  4ac
p
2a
;
with a= ðKa=dbÞ½Pt, b=1+Kað½Lti + ½Pt Þ , and c= dbKa½Lti, where di is
the absolute change in chemical shift for each titration point, [Lti] is
the total ligand concentration at each titration point, [Pt] is the total
protein concentration, Ka = 1/Kd is the binding constant, and db is
the chemical shift of the resonance in the complex [42]. Kd and db
were used as fitting parameters using the Xmgrace program (http://
plasma-gate.weizmann.ac.il/Grace/).
The proton chemical shifts of the bound glycyrrhizin were assigned
by 15N/13C filter, 15N/13C-filtered TOCSY (60 ms) and 15N/13C filter,
15N/13C-filtered NOESY (120 ms) experiments. Intermolecular nOes
between glycyrrhizin and box A were obtained from 2D NOESY exper-
iments with 15N/13C filter in F2 (mixing time 70–120 ms) [43]; protein
and ligand concentration were 0.6 mM and 0.9 mM, respectively.
Molecular Docking Calculations
Molecular docking of glycyrrhizin on HMG boxes (Protein Data Bank
[PDB] codes: 1aab and 1hmf) was performed using the software
HADDOCK 2.0_devel, which makes use of chemical-shift perturbation
data to drive the docking while allowing various degrees of flexibility
[26]. The protocol follows a three-stage docking procedure which in-
cludes (1) randomization of orientations and rigid body minimization,
(2) simulated annealing in torsion angle space, and (3) refinement in
Cartesian space with explicit water.
Residues showing chemical shifts larger than the average chemical-
shift difference plus one standard deviation were used to define active
residues according to the HADDOCK definition, and were used asChemistry & Biology 14,ambiguous interaction restraints (AIRs) [44] (Table 1). Residues that
were close to the threshold, or with small (<50%) solvent-accessible
surface areas, were not included in AIRs. Passive residues coincided
with the region which was allowed to be flexible during the semiflexible
simulated annealing step, as defined [26]. In the case of box A, inter-
molecular nOes were included as unambiguous restraints in the
calculations only in the final run (Table 1).
Optimized parameters for liquid simulation (OPLS) were used for the
protein (parallhdg5.3.pro and topallhdg5.3.pro). The geometric coordi-
nates and parameters for the ligand were calculated and optimized
using the PRODRG server [45].
During the rigid body docking, 1000 structures were calculated. The
best 300 solutions in terms of intermolecular energies were selected
for a semiflexible simulated annealing, followed by water refinement.
The analysis of the simulations was performed applying in-house
python and tcl scripts. Root-mean-square deviations (rmsd) were cal-
culated using the ProFit program (http://www.bioinf.org.uk/software/
profit/). The fitting of the protein was performed on the flexible residues
(Table 1) using the McLachlan algorithm [46]; the rmsd of glycyrrhizin
was calculated only on the heavy atoms of the triterpene scaffold.
The final rmsdmatrix was then clustered using the algorithm described
in Daura et al. [47], where a cluster is defined as an ensemble of at least
two conformations displaying an rmsd smaller than 0.8 A˚. The final
structures were clustered and scored using a combination of energy
terms (total energy, intermolecular van der Waals and electrostatic
energies, restraint energies) (Figures S2B and S3B).
Fluorescence Measurements
Experiments were performed on a Varian Eclipse instrument (Victoria,
Australia) with excitation at 273 nm (slit width 5 nm) and emission at
325 nm (slit width 5 nm). The initial protein concentration was 3 mM;
after each ligand addition, the samples were left to equilibrate for
5 min. The ligand concentration at the end of the titration was
250 mM for box B and 270 mM for box A and HMGB1; the added ligand
solution did not exceed 10% of the initial volume. At each data point,
the protein concentration was corrected for the dilution due to ligand
addition. All measurements were performed at 25C in 20 mM phos-
phate buffer (pH 7.2), 150 mM NaCl.
Dissociation constants (Kd) for box A and box Bwere estimated con-
sidering a single-step binding process with an equimolar stoichiome-
try. The free ligand concentration in solution was considered approxi-
mately equal to the total concentration of added ligand. Experimental
data were fitted by nonlinear regression (SigmaPlot 9.0, Systat Soft-
ware, San Jose, CA) to the equation (Equation 2):
F =F0  F0  FN½L0+Kd ½L0;
where F is the fluorescence intensity measured at each titration point,
[L0] is the total ligand concentration added at each point, F0 is the initial
fluorescence intensity of the unbound protein, and FN corresponds to
the fluorescence intensity of the bound final species.
Kd values for HMGB1 were estimated considering a mechanism in
which two ligand molecules bind simultaneously and independently431–441, April 2007 ª2007 Elsevier Ltd All rights reserved 439
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Glycyrrhizin Inhibits HMGB1 Activitiesto box A and box B. Experimental binding curves have been fitted
through the following equation (Equation 3):
F =F0;A  F0;A  FN;A½L0+KdA ½L0+F0;B 
F0;B  FN;B
½L0+KdB ½L0:
Notably, the calculated KdA and KdB were very similar; for this rea-
son, we then used a model where KdA = KdB = Kd,app and therefore
F =F0  2ðF0  FNÞ½L0½L0+Kd;app :
CD Spectroscopy
CD spectra were recorded at 293K on a Jasco 710 spectropolarimeter
(Tokyo, Japan). Cuvettes with a 0.1 cm path length were used.
Each spectrum was averaged using four accumulations collected in
0.1 nm intervals with an average time of 0.5 s. Typical protein concen-
tration was 5 mM, in 10 mM phosphate buffer (pH 7.2), 10 mM NaCl.
The same buffer was used to prepare a 10mM stock solution of glycyr-
rhizin, which was subsequently added to HMGB1.
Fluorescence Recovery after Photobleaching
FRAP was executed as described [30]. Cells were induced to undergo
apoptosis as described [4].
Supplemental Data
Supplemental Data include three figures and can be found with this ar-
ticle online at http://www.chembiol.com/cgi/content/full/14/4/431/
DC1/.
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